Literature DB >> 13356297

Differences between cancers in terms of evolution of drug resistance.

L W LAW.   

Abstract

Entities:  

Keywords:  NEOPLASMS/therapy

Mesh：

Year:  1956        PMID： 13356297

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  6 in total

1.  ISOLATION AND STUDY OF MUTANTS FROM MAMMALIAN CELLS IN CULTURE.

Authors:  I Lieberman; P Ove
Journal:  Proc Natl Acad Sci U S A       Date:  1959-06       Impact factor: 11.205

2.  A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.

Authors:  Adam C Palmer; Christopher Chidley; Peter K Sorger
Journal:  Elife       Date:  2019-11-19       Impact factor: 8.140

3.  Metabolism of 6-Mercaptopurine by Resistant Escherichia coli Cells.

Authors:  J H Coggin; M Loosemore; W R Martin
Journal:  J Bacteriol       Date:  1966-08       Impact factor: 3.490

4.  Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy.

Authors:  P Duesberg; R Stindl; R Hehlmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

Review 5.  Independent Drug Action in Combination Therapy: Implications for Precision Oncology.

Authors:  Deborah Plana; Adam C Palmer; Peter K Sorger
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

6.  Harnessing drug resistance: using ABC transporter proteins to target cancer cells.

Authors:  Heather M Leitner; Remy Kachadourian; Brian J Day
Journal:  Biochem Pharmacol       Date:  2007-05-21       Impact factor: 5.858
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.